Use of copeptin for rapid rule-out of acute myocardial infarction

Christian Mueller, Martin Möckel, Evangelos Giannitsis, Kurt Huber, Johannes Mair, Mario Plebani, Kristian Thygesen, Allan S Jaffe, Bertil Lindahl, ESC Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

50 Citations (Scopus)

Abstract

Copeptin is currently understood as a quantitative marker of endogenous stress. It rises rapidly in multiple acute disorders including acute myocardial infarction. As a single variable, it has only modest diagnostic accuracy for acute myocardial infarction. However, the use of copeptin within a dual-marker strategy together with conventional cardiac troponin increases the diagnostic accuracy and particularly the negative predictive value of cardiac troponin alone for acute myocardial infarction. The rapid rule-out of acute myocardial infarction is the only application in acute cardiac care mature enough to merit consideration for routine clinical care. However, the dual-marker approach seems to provide only very small incremental value when used in combination with sensitive or high-sensitivity cardiac troponin assays. This review aims to update and educate regarding the potential and the procedural details, as well as the caveats and challenges of using copeptin in clinical practice.

Original languageEnglish
JournalEuropean Heart Journal: Acute Cardiovascular Care
Volume7
Issue6
Pages (from-to)570-576
Number of pages7
ISSN2048-8726
DOIs
Publication statusPublished - 1 Sept 2018

Keywords

  • Journal Article

Fingerprint

Dive into the research topics of 'Use of copeptin for rapid rule-out of acute myocardial infarction'. Together they form a unique fingerprint.

Cite this